Product logins

Find logins to all Clarivate products below.


Cancer Pain | Current Treatment: Physician Insights | US | 2020

Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases). Treatment decisions are further complicated by differing patient responses to analgesics, intrusive side effects, and safety / tolerability issues that are pervasive among the many analgesic drug classes (e.g., opioid analgesics, antiepileptic drugs) prescribed for cancer pain. Currently, traditional opioid analgesics, most of which are generically available, dominate the treatment of cancer pain. With the exception of costly abuse-deterrent reformulations of certain opioid analgesics, no truly novel or mechanism-based therapies have launched in recent years. As cancer survival rates continue to grow and life expectancy increases, so too do the prevalence of cancer pain and the need for more analgesic treatments that are tolerable over the long term.

QUESTIONS ANSWERED

  • How is cancer pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
  • How do opioid analgesics with less abuse potential and therapies effective in treating neuropathic pain fit into the treatment algorithm for cancer pain?
  • What factors drive switching between or discontinuation of select analgesics?
  • How do physicians characterize recent changes in their treatment of cancer pain, and what changes to current usage do they expect within the next year?

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 50 U.S. oncologists and 50 U.S. pain specialists

KEY DRUGS COVERED: Fentanyl transdermal patch (Duragesic, generics), Nucynta IR / ER (tapentadol IR / ER), oxycodone CR / ER (OxyContin, generics; Xtampza ER), pregabalin (Lyrica, generics)

KEY INSIGHTS PROVIDED:

  • Factors influencing disease management and treatment decisions.
  • Drivers and constraints of treatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight on persistency and compliance.
  • Physician-reported recent/anticipated changes in brand usage or treatment approach.

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Ventolin HFA) and maintenance therapy to prevent…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD) resulting from insufficient erythropoietin production by impaired kidneys. The primary goal of renal anemia treatment is to…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…